Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment.

Hasan S, Cassinat B, Droin N, Le Couedic JP, Favale F, Monte-Mor B, Lacout C, Fontenay M, Dosquet C, Chomienne C, Solary E, Villeval JL, Casadevall N, Kiladjian JJ, Vainchenker W, Plo I.

Leukemia. 2014 Feb;28(2):460-3. doi: 10.1038/leu.2013.303. Epub 2013 Oct 22. No abstract available.

PMID:
24150219
[PubMed - indexed for MEDLINE]
3.

JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.

Hasan S, Lacout C, Marty C, Cuingnet M, Solary E, Vainchenker W, Villeval JL.

Blood. 2013 Aug 22;122(8):1464-77. doi: 10.1182/blood-2013-04-498956. Epub 2013 Jul 17.

PMID:
23863895
[PubMed - indexed for MEDLINE]
Free Article
4.

Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells.

Swierczek S, Nausova J, Jelinek J, Liu E, Roda P, Kucerova J, Jarosova M, Urbankova H, Indrak K, Prchal JT, Divoky V.

Am J Hematol. 2013 Feb;88(2):157-8. doi: 10.1002/ajh.23362. Epub 2012 Dec 24. No abstract available.

PMID:
23280542
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.

Kuriakose E, Vandris K, Wang YL, Chow W, Jones AV, Christos P, Cross NC, Silver RT.

Haematologica. 2012 Apr;97(4):538-42. doi: 10.3324/haematol.2011.053348. Epub 2011 Nov 18.

PMID:
22102708
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.

Gaikwad A, Nussenzveig R, Liu E, Gottshalk S, Chang K, Prchal JT.

Exp Hematol. 2007 Apr;35(4):587-95.

PMID:
17379069
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations.

Li S, Kralovics R, De Libero G, Theocharides A, Gisslinger H, Skoda RC.

Blood. 2008 Apr 1;111(7):3863-6. doi: 10.1182/blood-2007-09-111971. Epub 2008 Jan 14.

PMID:
18195094
[PubMed - indexed for MEDLINE]
Free Article
8.

Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.

Ishii T, Bruno E, Hoffman R, Xu M.

Blood. 2006 Nov 1;108(9):3128-34. Epub 2006 Jun 6.

PMID:
16757685
[PubMed - indexed for MEDLINE]
Free Article
9.

[Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].

Bai J, Xue YP, Zhang L, Li CH, Fan DM, Li B, Xu SC, Li DP, Sun XJ, Jiang B, Yang RC.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Apr;19(2):444-9. Chinese.

PMID:
21518505
[PubMed - indexed for MEDLINE]
10.

Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.

Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL.

Exp Hematol. 2008 Nov;36(11):1480-6. doi: 10.1016/j.exphem.2008.05.006. Epub 2008 Aug 23.

PMID:
18723264
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera.

Toogeh G, Ferdowsi S, Naadali F, Alimoghaddam K, Ghavamzadeh A, Shirkoohi R, Ghaffari SH.

Med Oncol. 2011 Dec;28(4):1555-8. doi: 10.1007/s12032-010-9570-8. Epub 2010 May 25.

PMID:
20499211
[PubMed - indexed for MEDLINE]
12.

Polycythemia vera is not initiated by JAK2V617F mutation.

Nussenzveig RH, Swierczek SI, Jelinek J, Gaikwad A, Liu E, Verstovsek S, Prchal JF, Prchal JT.

Exp Hematol. 2007 Jan;35(1):32-8.

PMID:
17198871
[PubMed - indexed for MEDLINE]
13.

Imatinib effect on growth and signal transduction in polycythemia vera.

Gaikwad A, Verstovsek S, Yoon D, Chang KT, Manshouri T, Nussenzveig R, Cortes J, Vainchenker W, Prchal JT.

Exp Hematol. 2007 Jun;35(6):931-8.

PMID:
17533047
[PubMed - indexed for MEDLINE]
14.

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, Van Etten RA.

PLoS One. 2006 Dec 20;1:e18.

PMID:
17183644
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.

Stauffer Larsen T, Iversen KF, Hansen E, Mathiasen AB, Marcher C, Frederiksen M, Larsen H, Helleberg I, Riley CH, Bjerrum OW, Rønnov-Jessen D, Møller MB, de Stricker K, Vestergaard H, Hasselbalch HC.

Leuk Res. 2013 Sep;37(9):1041-5. doi: 10.1016/j.leukres.2013.06.012. Epub 2013 Jul 1.

PMID:
23827351
[PubMed - indexed for MEDLINE]
16.

Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera.

Larsen TS, Bjerrum OW, Pallisgaard N, Andersen MT, Møller MB, Hasselbalch HC.

Ann Hematol. 2008 Oct;87(10):847-50. doi: 10.1007/s00277-008-0498-4. Epub 2008 May 15.

PMID:
18481066
[PubMed - indexed for MEDLINE]
17.

The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice.

Abe M, Funakoshi-Tago M, Tago K, Kamishimoto J, Aizu-Yokota E, Sonoda Y, Kasahara T.

Int Immunopharmacol. 2009 Jul;9(7-8):870-7. doi: 10.1016/j.intimp.2009.03.011. Epub 2009 Mar 25.

PMID:
19327411
[PubMed - indexed for MEDLINE]
18.

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.

Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S.

J Clin Oncol. 2009 Nov 10;27(32):5418-24. doi: 10.1200/JCO.2009.23.6075. Epub 2009 Oct 13.

PMID:
19826111
[PubMed - indexed for MEDLINE]
Free Article
19.

Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F.

Steimle C, Lehmann U, Temerinac S, Goerttler PS, Kreipe H, Meinhardt G, Heimpel H, Pahl HL.

Ann Hematol. 2007 Apr;86(4):239-44. Epub 2007 Jan 26.

PMID:
17256145
[PubMed - indexed for MEDLINE]
20.

The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.

Zhan H, Spivak JL.

Clin Adv Hematol Oncol. 2009 May;7(5):334-42. Review.

PMID:
19521323
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk